BioCentury | Jun 3, 2020
Finance

June 2 Financial Quick Takes: follow-ons for Allogene, Adaptimmune, plus DCVC Bio, Windtree and BMS

Allogene raises $550M follow-on  Allogene Therapeutics Inc. (NASDAQ:ALLO) raised $550 million late Monday through the sale of 11.7 million shares at $47, a 2% discount to its Friday close of $48.16, before proposing the offering...
BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

CNS disorders company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced Mark Schneyer as its first CBO. He was VP, business development at the Upjohn unit of Pfizer Inc. (NYSE:PFE). Hansa Biopharma AB (SSE:HNSA) said Achim Kaufhold will...
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

Ginkgo financing to support COVID-19 testing  New investor Illumina Inc. (NASDAQ:ILMN) led a $70 million round on Thursday for genetic engineering company Ginkgo Bioworks Inc.; existing investors General Atlantic and Viking Global Investors also participated....
BioCentury | Feb 29, 2020
Management Tracks

Brandicourt joins Alnylam's board: plus Bayer, Jazz, Halozyme, Arena, Aurinia, Adverum, Neoleukin, Centogene, Epirium, Insilico, Nouscom, Eloxx, Nordic, Summit,

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said Olivier Brandicourt will join its board. Brandicourt, who retired as CEO of Sanofi (Euronext:SAN; NASDAQ:SNY) last year, also plans to join Blackstone Group as a senior adviser....
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BC Week In Review | Jan 18, 2019
Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
BC Extra | Jan 17, 2019
Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
BC Week In Review | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) in a Nov. 15 deal that highlights how far Arena’s come since it shifted its focus...
BC Extra | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) on Thursday in a deal that highlights how far Arena’s come since it shifted its focus...
Items per page:
1 - 10 of 626
BioCentury | Jun 3, 2020
Finance

June 2 Financial Quick Takes: follow-ons for Allogene, Adaptimmune, plus DCVC Bio, Windtree and BMS

Allogene raises $550M follow-on  Allogene Therapeutics Inc. (NASDAQ:ALLO) raised $550 million late Monday through the sale of 11.7 million shares at $47, a 2% discount to its Friday close of $48.16, before proposing the offering...
BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

CNS disorders company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced Mark Schneyer as its first CBO. He was VP, business development at the Upjohn unit of Pfizer Inc. (NYSE:PFE). Hansa Biopharma AB (SSE:HNSA) said Achim Kaufhold will...
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

Ginkgo financing to support COVID-19 testing  New investor Illumina Inc. (NASDAQ:ILMN) led a $70 million round on Thursday for genetic engineering company Ginkgo Bioworks Inc.; existing investors General Atlantic and Viking Global Investors also participated....
BioCentury | Feb 29, 2020
Management Tracks

Brandicourt joins Alnylam's board: plus Bayer, Jazz, Halozyme, Arena, Aurinia, Adverum, Neoleukin, Centogene, Epirium, Insilico, Nouscom, Eloxx, Nordic, Summit,

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said Olivier Brandicourt will join its board. Brandicourt, who retired as CEO of Sanofi (Euronext:SAN; NASDAQ:SNY) last year, also plans to join Blackstone Group as a senior adviser....
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BC Week In Review | Jan 18, 2019
Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
BC Extra | Jan 17, 2019
Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
BC Week In Review | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) in a Nov. 15 deal that highlights how far Arena’s come since it shifted its focus...
BC Extra | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) on Thursday in a deal that highlights how far Arena’s come since it shifted its focus...
Items per page:
1 - 10 of 626